Pioneering Pharmaceutical Industry
Pioneering Pharmaceutical Industry

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2024-08-05

Starting Again! Pioneer Pharmaceuticals KX-826 Tincture Registrational Clinical Trial Investigators Meeting Successfully Held

BEIJING, Aug. 5, 2024 - Pioneering Pharmaceuticals (HKEx: 9939.HK), a biopharmaceutical company focusing on the research, development and industrialization of potentially first-of-its-kind and best-of-breed innovative medicines, announced that the investigators' meeting of the Registered Phase II/III Clinical Trial of KX-826 Tincture for the Topical Treatment of Androgenetic Alopecia in Chinese Adult Males (AGA), which is being conducted by Prof. Zhang Jianzhong and Prof. Zhou Cheng of Peking University People's Hospital as Leading PIs, was successfully held in Beijing, China, on Aug. 4th.
Picture Name

2024-07-10

Cosmetics with KX-826 as the core ingredient launched for sale

Beijing, July 10, 2024, Pioneering Pharmaceuticals (stock code: 9939.HK), announced that after its self-developed KX-826 was awarded the International Named Cosmetic Ingredient (INCI) designation, the cosmetic products with KX-826 as the main ingredient have been officially launched for sale globally in the recent days, and the first product is the topical anti-baldness solution targeting at androgenic alopecia (AGA).
Picture Name

2024-07-01

KX-826 Androgen receptor antagonist

KX-826 is a topical androgen receptor (AR) antagonist, the world's first AR antagonist for the treatment of alopecia areata to enter registrational Phase III clinical trials.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor